In MDA-MB-231 breast cancer cells, reduced mRNA expression of EZH2 was detected upon DZNepA treatment whereas increased expression of its target genes (except POMT2 and VGLL4) was found (Fig. 10B). This evidence concerns the gene POMT2 and breast cancer.